Your browser doesn't support javascript.
loading
The HDL particle composition determines its antitumor activity in pancreatic cancer.
Oberle, Raimund; Kührer, Kristina; Österreicher, Tamina; Weber, Florian; Steinbauer, Stefanie; Udonta, Florian; Wroblewski, Mark; Ben-Batalla, Isabel; Hassl, Ingrid; Körbelin, Jakob; Unseld, Matthias; Jauhiainen, Matti; Plochberger, Birgit; Röhrl, Clemens; Hengstschläger, Markus; Loges, Sonja; Stangl, Herbert.
Afiliação
  • Oberle R; Center for Pathobiochemistry and Genetics, Medical University of Vienna, Vienna, Austria raimund.oberle@meduniwien.ac.at.
  • Kührer K; Center for Pathobiochemistry and Genetics, Medical University of Vienna, Vienna, Austria.
  • Österreicher T; Center for Pathobiochemistry and Genetics, Medical University of Vienna, Vienna, Austria.
  • Weber F; School of Medical Engineering and Applied Social Sciences, University of Applied Sciences Upper Austria, Linz, Austria.
  • Steinbauer S; Center of Excellence Food Technology and Nutrition, University of Applied Sciences Upper Austria, Wels, Austria.
  • Udonta F; Department of Oncology, Hematology and Bone Marrow Transplantation, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Wroblewski M; Department of Oncology, Hematology and Bone Marrow Transplantation, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Ben-Batalla I; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hassl I; Center for Pathobiochemistry and Genetics, Medical University of Vienna, Vienna, Austria.
  • Körbelin J; ENDomics Lab, Department of Oncology, Hematology and Bone Marrow Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Unseld M; Department of Medicine I, Division of Palliative Medicine, Medical University of Vienna, Vienna, Austria.
  • Jauhiainen M; Minerva Foundation Institute for Medical Research and Finnish Institute for Health and Welfare, Genomics and Biobank Unit, Biomedicum 2U, Helsinki, Finland.
  • Plochberger B; School of Medical Engineering and Applied Social Sciences, University of Applied Sciences Upper Austria, Linz, Austria.
  • Röhrl C; Center of Excellence Food Technology and Nutrition, University of Applied Sciences Upper Austria, Wels, Austria.
  • Hengstschläger M; Center for Pathobiochemistry and Genetics, Medical University of Vienna, Vienna, Austria.
  • Loges S; Department of Personalized Oncology, University Hospital Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Stangl H; Center for Pathobiochemistry and Genetics, Medical University of Vienna, Vienna, Austria.
Life Sci Alliance ; 5(9)2022 09.
Article em En | MEDLINE | ID: mdl-35577388
ABSTRACT
Despite enormous efforts to improve therapeutic options, pancreatic cancer remains a fatal disease and is expected to become the second leading cause of cancer-related deaths in the next decade. Previous research identified lipid metabolic pathways to be highly enriched in pancreatic ductal adenocarcinoma (PDAC) cells. Thereby, cholesterol uptake and synthesis promotes growth advantage to and chemotherapy resistance for PDAC tumor cells. Here, we demonstrate that high-density lipoprotein (HDL)-mediated efficient cholesterol removal from cancer cells results in PDAC cell growth reduction and induction of apoptosis in vitro. This effect is driven by an HDL particle composition-dependent interaction with SR-B1 and ABCA1 on cancer cells. AAV-mediated overexpression of APOA1 and rHDL injections decreased PDAC tumor development in vivo. Interestingly, plasma samples from pancreatic-cancer patients displayed a significantly reduced APOA1-to-SAA1 ratio and a reduced cholesterol efflux capacity compared with healthy donors. We conclude that efficient, HDL-mediated cholesterol depletion represents an interesting strategy to interfere with the aggressive growth characteristics of PDAC.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Life Sci Alliance Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Áustria

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Life Sci Alliance Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Áustria